Merck Boosts Sales Forecast on Strong Keytruda and New Drug Uptake

Merck, a leading pharmaceutical company, has raised its sales forecast following strong earnings in the second quarter. The company's revenue rose by 5% year-over-year, beating expectations. Keytruda, Merck's blockbuster cancer drug, continued to drive growth, as did newer drugs like Winrevair.

The adjusted loss per share of $0.13 was lower than expected, with analysts forecasting a loss of $0.23. The company attributed the success to the strong performance of its key products and the increasing demand for newer treatments.

Merck's Q2 earnings report demonstrates the company's ability to adapt to changing market conditions and capitalize on emerging trends in the pharmaceutical industry.